Chiesi Group is buying KalVista Pharmaceuticals in a roughly $1.9 billion deal to expand its rare disease portfolio with Ekterly (sebetralstat), an oral on-demand therapy for hereditary angioedema (HAE). The acquisition, valued at about $1.9 billion, brings KalVista’s FDA-approved plasma kallikrein inhibitor under Chiesi’s umbrella and adds an established commercial asset. KalVista reported about $49 million in Ekterly sales in the first year on the market following FDA approval in July 2025, with additional approvals across the U.S., UK, EU and Japan. Chiesi said it expects to maintain commercial momentum and ensure patient access during integration, with the transaction expected to close in Q3 2026. Chiesi called the move its largest acquisition to date, positioning the deal as part of a broader rare disease expansion strategy and potentially strengthening its presence in the U.S. rare immunology market.